BioSpace News Archive

Prelude Corporation announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting.

Visby Medical™, an innovative diagnostic company, announced its agreement with Urgent Care for Children to offer the company’s new Sexual Health Click Test to patients for the detection of sexually transmitted infections in female patients 14 years of age and older.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer.

Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.

Ribon Therapeutics today announced the first patient has been dosed in the Phase 1b/2 study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung (SCCL).

Recordati Rare Diseases Announce Publication in T he Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming Efficacy and Safety of ISTURISA ® (osilodrostat) in Patients With Cushing’s Disease, The LINC 4 study demonstrated superiority of ISTURISA ® (osilodrostat) over placebo in achieving cortisol control during the 12-week, double-blind, randomized phase (77% vs 8%, P <0.0001). ISTURISA provided rapid and s

Artizan Biosciences, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform.

Monte Rosa Therapeutics, Inc. today reported business highlights and financial results for the fourth quarter and full year, ended December 31, 2021.

Gain Therapeutics, Inc., a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, presented new pre-clinical data from its Gaucher Disease program.

Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the fourth quarter and full year ended December 31, 2021 and provides business highlights.